sabato, 5 dicembre 2020
Medinews
20 Novembre 2018

FDA Approves Brentuximab Vedotin for Frontline CD30+ PTCL

November 16, 2018 – The FDA has approved brentuximab vedotin for use in combination with chemotherapy for the frontline treatment of patients with CD30-expressing peripheral T-cell lymphoma (PTCL). The approval, which follows a breakthrough therapy designation, is based on the phase III ECHELON-2 trial, in which combining frontline brentuximab vedotin with CHP (cyclophosphamide, doxorubicin, prednisone) reduced the risk of death by 34% … (leggi tutto)

TORNA INDIETRO